Current Treatment Strategy in Langerhans Cell Histiocytosis

Langerhans cell histiocytosis (LCH) is a rare disorder described as three different entities including eosinophilic granuloma of bone, the Hand-Schuller-Christian syndrome, and Letterer-Siwe disease. LCH is currently classified into single system LCH, and multisystem LCH. Patients with single system LCH have an excellent prognosis, and are mostly treated with local therapy. Multisystem LCH is subdivided into low risk and high risk groups. A 6-week course of PRED/VBL is recommended for all patients with MS-LCH. Further therapy depends on the response to the initial course, and risk group of the patient.